May 15, 2017

Can a change to Canada’s SR&ED Program Encourage Clinical Trials for Rare Diseases?

publicpolicydraft for comments

Ottawa, ON..
.CATAAlliance, Canada’s one voice for innovation lobby group, has announced a new advocacy campaign for changes to SR&ED to help reverse a marked lack of clinical trials in Canada for rare (orphan) diseases.

CATA CEO John Reid said, “ Compared to Americans, Canadians have relatively little access to medical innovations for serious conditions, such as rare cancers” adding, “ This is a small, but critically important gap, that could be fixed through a carefully crafted SR&ED change “

A comprehensive review of the SR&ED program now being conducted under the leadership of Russ Roberts, Sr. VP, CATAAlliance, is calling for:

–       Enhanced SR&ED rate for clinical trials conducted in Canada, narrowly targeted to trials for rare (orphan) diseases

–       Super-enhanced SR&ED rate where the trial includes an open-access arm (i.e. access those who don’t qualify for the experimental arm)

–       Making manufactured materials required for trials clearly SR&ED-able

–       To cover the cost of animal studies including the CRO (contract research organization – i.e. lab)

–       To cover up to 50% of the cost of each human subject in the clinical trial for orphan drugs

–       Making the credit refundable, even for non-CCPCs

andreajohnsonAdd video interview(s), Andrea Johnson, Partner, DENTONS

Reid concluded, “ We think the cost of this program, packaged with minor non-SRED regulatory changes would be minimal;  it would bring innovation to Canada in terms of enhancing medical R&D centres; and most important help Canadians with rare diseases.”

Do you have guidance for us or an interest in helping advance this campaign? then please contact CATA CEO, John Reid at


cataimage-150x150About CATAAlliance

Interact with your Innovation Peer Group Now

The Canadian Advanced Technology Alliance (CATAAlliance) is Canada’s One Voice for Innovation Lobby Group, crowdsourcing ideas and guidance from thousands of opt in members in moderated social networks in Canada and key global markets. (No Tech Firm Left Behind)

Contact: CATA CEO, John Reid at